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Mucinous bronchioloalveolar carcinoma (M-BAC), a rarecancer, has been found to be singularly refractory to the
tyrosine kinase inhibitors, gefitinib and erlotinib. Response to
chemotherapy is less well-documented. As regards the ty-
rosine kinase inhibitors, this seems related to the high fre-
quency of Kras mutations in M-BAC.1,2 Herein is a report of
M-BAC responding in a rapid and dramatic fashion to sec-
ond-line pemetrexed, the second such reported case,3 and the
first with molecular correlates.
CASE REPORT
A 62-year-old, long-time smoking, man developed a pro-
ductive cough with clear sputum in August 2009. Chest x-ray
(Figure 1A) showed bilateral infiltrates with a pleural effusion.
Treatment was begun with oral antibiotics. Nevertheless, with
no clinical improvement, computed tomography scan (Figure
1B) also showed infiltrates. Sputum production and pulmonary
infiltrates increased and bronchoscopy with biopsy in November
yielded the diagnosis of M-BAC (Fig. 2A). Sputum production
was mainly nocturnal, approximately 30 ml/24 hours, and there
was associated orthopnea, shortness of breath, and dyspnea on
exertion. Carboplatin and paclitaxel were started, two courses, 3
weeks apart. Nevertheless, at 6 weeks, repeat imaging showed
progressive disease, and there were worsening symptoms. Be-
cause of a recent case report of such a patient responding to
pemetrexed,3 administration of pemetrexed was begun in Janu-
ary 2010. Within 1 week, sputum production had significantly
decreased, and he had other symptom improvement. Chest
computed tomography in February confirmed radiographic im-
provement. Pemetrexed was continued, and by July, all symp-
toms were substantially less through December (Figure 1C, D).
Molecular correlates demonstrated 1 to 2 nuclear
staining (20% of tumor cells) for thymidylate synthase (TS)
(Figure 2D), 3 membrane staining for folate receptor (FR)
alpha (30% of tumor cells) (Figure 2C), and 4 staining for
Ki-67 (90% of tumor cells) (Figure 2B). Kras was not
found to be mutated, although few cells were available.
Comment
Reports on the effects of chemotherapy on the BACs,
whether nonmucinous or mucinous, are scanty but suggest
response rates lower than for other types of non-small cell lung
cancers.1,2 M-BAC, soon to be called mucinous adenocarci-
noma, can be aggressive, especially when in the pneumonic
form, as in this case in which heavy sputum production was a
serious problem.
As to why pemetrexed was so quickly effective in this
and the previously reported case, there can only be conjec-
ture. Responses of non-small cell lung cancer to pemetrexed
appear to be related both to histology, with squamous cell
carcinomas responding less well compared with nonsqua-
mous types, and to TS level, with a low level of expression
being favorable as regards response.4 Although not quantifi-
able in this case, TS expression level was not felt to be high.
On the other hand, BAC tumors overexpress FR alpha, a
high affinity but low capacity folate/antifolate transporter with
higher affinity for pemetrexed than folic acid. Thus, FR alpha is
involved in pemetrexed intracellular transport and its cytotoxic
activity and is expressed in BAC 2.6 times higher than in lung
adenocarcinoma cell lines.5 Therefore, pemetrexed efficacy
could correlate with FR alpha expression, in this case, 3, and
be a predictive factor for tumors with high expression.
Although there are two reported cases of nonmuci-
nous-BAC also having durable responses to pemetrexed,6
it is probably a different disease from M-BAC.1,2 Why
both types appear to have an unusual sensitivity to pem-
etrexed remains unexplained.
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FIGURE 1. A, PA chest x-ray at
presentation. B, CT chest after 1
month of antibiotics, showing right
lung infiltrate (arrow) and mass (X).
C, PA after 6 months of pem-
etrexed. D, CT chest after 6 months
of pemetrexed, showing the infil-
trate almost gone, mass much
smaller (arrow). PA, ●●●; CT, com-
puted tomography.
FIGURE 2. A, Low-power view at
time of diagnosis. B, Ki-67 staining
4. C, Folate receptor alpha mem-
brane staining 3. D, Thymidylate
synthase nuclear staining 1 to 2.
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